Research programme: plasma-derived biopharmaceuticals - ProMetic Life Sciences

Drug Profile

Research programme: plasma-derived biopharmaceuticals - ProMetic Life Sciences

Alternative Names: Alpha-1 antitrypsin deficiency therapy - ProMetic Life Sciences; C1 INH - ProMetic Life Sciences; Haemophilia therapeutics - ProMetic Life Sciences; Plasma-derived orphan drug products - ProMetic Life Sciences

Latest Information Update: 11 Jan 2017

Price : $50

At a glance

  • Originator ProMetic Life Sciences
  • Class Acute-phase proteins; Alpha globulins; Blood proteins; Secretory proteinase inhibitory proteins; Serpins
  • Mechanism of Action Alpha 1-antitrypsin replacements; Blood coagulation stimulants; Complement C1 inhibitors; Serine endopeptidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Alpha 1-antitrypsin deficiency
  • Research Haemophilia; Hereditary angioedema

Most Recent Events

  • 05 Jan 2017 ProMetic BioSciences and Hematech BioTherapeutics terminate their licensing agreement related to plasma-derived biopharmaceuticals
  • 07 May 2015 Early research in Hereditary angioedema in Canada (unspecified route)
  • 07 May 2015 ProMetic Life Sciences plans phase I development for Hereditary angioedema
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top